Keith Murphy, CEO of Viscient Biosciences, discusses the process of developing a 3D bioprinted tissue model and their potential in developing therapeutics for COVID-19 and other diseases.
List view / Grid view
Filter the results
The team found that the expression of the APOE4 gene variant in pericytes caused amyloid plaque formation in a blood-brain barrier model.
The loss of retinal light-sensing photoreceptor cells is a leading cause of blindness and the number of individuals affected by retinal degenerative diseases is increasing with an ageing population. Currently, there are no treatments for these diseases and progress in finding new treatments is slow. This article explores the potential…
The latest generation of three-dimensional (3D) cell models offer new and exciting possibilities for pharmaceutical research. However, deciding how to capture sufficient information in the most efficient way from an experiment without making the data size overwhelming can prove challenging. Margaritha Mysior and Jeremy Simpson discuss the opportunities and challenges…
Current state of NAFLD treatments and the promise of in vitro platforms towards better screening of drug candidates
The heterogeneous pathogenesis of metabolic fatty liver diseases presents researchers with numerous challenges when trying to develop a treatment. This article explores the spectrum of these diseases and presents a novel in vitro platform for screening drug candidates.
A new paper describes the first full study of the epigenetics of human tumour organoids, suggesting this could be used to develop novel oncology treatments.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
Organoids at different stages of non-alcoholic steatohepatitis (NASH) progression have been created to help in drug design and identification of diagnostic biomarkers.
Recombinant angiotensin converting enzymes (ACE2) reduced infection and viral growth in cell cultures and organoids by acting as a decoy for SARS-CoV-2.
A collapsible basket technology has been developed to significantly accelerate the analysis process when scientists are developing new medicines.
The model was tested on a panel of drugs that are both still on the market or have been recalled due to adverse effects and was able to show their toxicity.
New technology is for the first time enabling scientists to analyse the individual behaviour of millions of different cells living inside lab-grown tumours, which could lead to new personalised cancer treatments.
More effective drugs could be developed due to a new technique that has allowed scientists to decipher how millions of individual cells are communicating with each other on miniature tumours grown in a lab.